NCT00793273已完成不适用
Evaluation of Glycaemic Control After Initiation of Levemir® in Patients With Type 2 Diabetes Mellitus and Time Period Between Diagnosis of Type 2 Diabetes Mellitus and Insulin Initiation.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,074
- 主要终点
- Change in FPG (fasting plasma glucose) of treatment
研究概览
简要总结
This study is conducted in Europe. The aim of this observational study is to observe the efficacy of Levemir® treatment in patients with type 2 diabetes in everyday clinical practice in Switzerland. Furthermore the time period between diagnosis of type 2 diabetes and insulin initiation is evaluated.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes mellitus
- •Insulin-naive or currently treated with another basal insulin
- •Inclusion of patients at the discretion of the treating physician after the decision to prescribe Levemir®
排除标准
- •Type 1 diabetes mellitus
- •Patients treated with short acting or with premix insulin
- •Women who are pregnant, breast feeding or have the intention to become pregnant
- •Known or suspected allergy to the study product or related product
- •Any exclusion criteria according to the Swiss Levemir® SPC (Summary of Product Characteristics)
研究组 & 干预措施
A
干预措施: insulin detemir (Drug)
结局指标
主要结局
Change in FPG (fasting plasma glucose) of treatment
时间窗: after 12 to 16 weeks
Change in HbA1c of treatment
时间窗: after 12 to 16 weeks
次要结局
- Insulin dose and concomitant oral antidiabetic medication time period between diagnosis of type 2 diabetes and insulin initiation(after 12 to 16 weeks)
- Occurrence of adverse events(after 12 to 16 weeks)
研究者
相似试验
已完成
不适用
Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose ControlDiabetesDiabetes Mellitus, Type 2NCT00700960Novo Nordisk A/S2,745
已完成
不适用
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes MellitusDiabetesDiabetes Mellitus, Type 2NCT00687284Novo Nordisk A/S2,188
已完成
不适用
Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT00699179Novo Nordisk A/S2,308
已完成
不适用
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern InsulinDiabetesDiabetes Mellitus, Type 2NCT00670722Novo Nordisk A/S6,500
已完成
不适用
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)DiabetesDiabetes Mellitus, Type 2NCT00657930Novo Nordisk A/S2,289